Search results for "PCR POSITIVE CONTROLS"

4 results for "PCR POSITIVE CONTROLS" - showing 1-4

Display

< >

<< Previous Next >>

Application Data (Published customer imageSLAMF3 blockade in human hepatocytes is associated with lower susceptibility to HCV. (A) SLAMF3 was stained in primary human hepatocytes (PHHs) and cells from the Huh-7 human hepatoma cell line with a specific antibody (HLy9.1.25 clone; grey) and an isotype-matched control (empty). One of four independent experiments is shown. Huh-7 cells were transfected with scrambled control (sc) siRNA or three specific siRNAs (#1, #2 and #3) targeting SLAMF3, prior to infection with HCVcc; siRNA efficiency was checked by quantifying SLAMF3 mRNA (B) and the CD81 expression level (C) by flow cytometry analysis at 48 h post-transfection. Results are presented as the mean +/-SD (n = 3). Intracellular viral RNA was quantified at 72 h p.i. (D) and the infection was measured at 72 h p.i. by focus-forming units FFUs counting (E) (as inhibition percent; mean of three independent experiments; error bars: SD. **p)

Application Data (Published customer image: Effect of SLAMF3 expression on the organization of the actin cytoskeleton. Cells (Huh-7) were stained with phalloidin (rhodamine, red) and anti-SLAMF3 (FITC, green) and SLAMF3 positive (Huh-7-SLAMF3pos) and SLAMF3-negative (Huh-7-SLAMF3pos) cells were examined under the microscope. One representative of two independent experiments is shown.From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)

Application Data (Published customer image: Expression of SLAM-R family by HHPHs and Huh-7 and HepG2 human HCC cell lines. SLAM-Rs were stained with specific antibodies against SLAMF1 (CD150), SLAMF2 (CD84), SLAMF4 (CD224) and SLAMF6 (NTBA) (grey) or with matched isotype controls (empty). One of four independent experiments is shown.From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)

Application Data (Published customer image: Expression of SLAMF3 assessed by flow cytometry analysis after transfection with vector coding for SLAMF3 or an empty vector (Mock) in Huh-7 and HepG2 cells. SLAMF3 staining (in grey) is overlaid by negative control (in white). One of four independent experiments is shown. doi:10.1371/journal.pone.0082918.s002From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)

Application Data (Published customer image: Restoration of SLAMF3 expression in HCC cells inhibits MAPK ERK1/2, JNK and mTOR pathways and induces caspase-dependent apoptosis.(A) SLAMF3 expression was confirmed by Western blot analysis in SLAMF3-over-expressing Huh-7 and mock cells at 48 h post-transfection. ERK1/2, JNK, p38, AKT and mTOR proteins were detected as controls. The activation levels of MAPK ERK1/2 (Thr 202/Tyr 204), JNK (Thr 183/Tyr 185), p38 (Thr 180/Tyr 183), PI3K (p85/p110 Thr 467/Tyr 199), AKT (Ser 473, Thr 308) and mTOR (Ser 2448, Ser 2481) are represented. One of three representative experiments is shown here. (B) The results of an active caspase assay based on cell-permeable fluorochrome inhibitor of caspases (FLICA). Caspase activity was evaluated in HCC cells (Huh-7 and HepG2 lines) at the indicated times after the ectopic introduction of SLAMF3 vector. Caspase activity is shown in the SLAMF3neg subpopulation (in white) and the SLAMF3pos (overlaid in grey) subpopulation from one representative of two independent experiments.From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)

Application Data (Published customer image: SLAMF3 expression is repressed in tumour cells from ten resected HCC patients. (A) SLAMF3 mRNA expression was analysed in hepatocytes from resected HCC patients. Specific amplification of SLAMF3 mRNAs using PCR (representative patients #2, #7 and #12) and quantitative PCR in tumour tissues (T) and peritumoral tissues (pT) presented separately (B) and as median (**p)

Application Data (Published customer image SLAMF3 over-expression increases hepatocyte permissiveness to HCV. Huh-7 cells were transfected with empty vector pBud (mock) or human SLAMF3 (to yield Huh-7+ cells) and incubated with HCVcc. (A) SLAMF3 expression was analyzed by flow cytometry (HLy9.1.25 clone) and (B) visualized by confocal microscopy in one out of three experiment. Unshaded histograms show the isotype-matched control (Co) and shaded histograms show SLAMF3 expression). (C, D, E) Infection was assessed at 4 and 72 h p.i. as the number of FFUs and (F and G) by flow cytometry analysis; (C) intracellular E2 (stained red) were measured at 4 h and 72 h p.i. Green staining corresponds to the SLAMF3 expression. One of three representatives independent experiments is shown. (D) The HCV permissiveness of Huh-7 mock and Huh-7+ cells was evaluated in terms of the number of FFUs based on intracellular E2 viral protein staining and (E) fluorescent microscopy analysis (mean of five experiments; error bars: SD; *p)

Application Data (Staining of human peripheral blood lymphocytes with Mouse anti Human CD229 : RPE)

Application Data (Published customer image: Correlation between SLAMF3 expression and HCC cell proliferation.(A) Effects of the introduction of specific siRNAs on SLAMF3 expression in Huh-7 cells. Cells were transiently transfected with a scrambled siRNA (Sc) or one of two pre-designed anti-SLAMF3 siRNAs (referred to as #2 and # 3); SLAMF3 expression was measured by Western blot analysis (anti-SLAMF3, K12). One representative of two independent experiments is shown. (B) siRNA-treated Huh-7 cells were cultured and proliferation was assayed in a Trypan blue exclusion test after 48 h. Proliferation is presented as the mean number of viable cells +/- SD (n = 5; statistical significance: ***p)

Application Data (Staining of human peripheral blood lymphocytes with Mouse anti Human CD299: Azide Free)

CD229, Monoclonal Antibody (Cat# AAA11951)

Full Name

MOUSE ANTI HUMAN CD229

Gene Names

LY9; hly9; mLY9; CD229; SLAMF3

Applications

Flow Cytometry, Immunoprecipitation

Pricing

< >

<< Previous Next >>

WB (Western Blot) (Figure 12 Overexpression Validation in Spike Transfected 293 Cells Loading: 15 ug per lane of 293 cell lysate. Antibodies: SARS-CoV-2 (COVID-19) Spike, AAA10931 (1 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: WT293 cells and Lane 2: SARS-CoV-2 Spike overexpressed 293 cells.)

IHC (Immunohistochemistry) (Figure 11 IHC Validation of SARS-CoV2 Spike in COVID-19 Patient Brain Spike protein was detected by anti-spike antibodies (AAA10931, 0.2 ug/mL) in the brain of the COVID-19 patient confirmed by PCR. (Courtesy of Dr. Nuovo Gerard J., OSU))

IHC (Immunohistochemistry) (Figure 10 IHC Validation of SARS-CoV2 Spike in COVID-19 Patient Lung Strong spike signal was detected by anti-spike antibodies (AAA10931, 0.2 ug/mL) in the lung of the COVID-19 patient confirmed by PCR. (Courtesy of Dr. Nuovo Gerard J., OSU))

IHC (Immunohistchemistry) (Figure 9 IHC Validation of SARS-CoV2 Spike in the Nasopharyngeal Swab Sample of the COVID-19 Patient Strong spike signal was detected by anti-spike antibodies (AAA10931, 0.2 ug/mL) in the nasopharyngeal swab sample of the COVID-19 patient and no spike signal was observed in the sample of the COVID-19 negative patient. COVID-19 cases were confirmed by PCR. (Courtesy of Dr. Nuovo Gerard J., OSU))

IF (Immunofluorescence) (Figure 8 IF Validation of SARS-CoV2 Spike in COVID-19 Patient Skin (Magro et al., 2020) C4d is highlighted green while COVID-19 spike protein detected by anti-spike antibodies (AAA10931, 0.2 ug/mL) shows a red staining pattern; a yellow signal is discernible indicative of co-localization of C4d and viral protein within the microvasculature.)

IF (Immunofluorescence) (Figure 7 IF Validation of SARS-CoV2 Spike in COVID-19 Patient Lung (Magro et al., 2020) SARS-CoV2 spike protein (red, panel C) detected by anti-spike antibodies (AAA10931, 0.2 ug/mL) colocalized with C4d (green in panel d, merged in yellow). Spike protein (red, panel g) was also colocalized with C5b-9 (green in panel f&h, merged in yellow))

IHC (Immunohistchemistry) (Figure 6 IHC/IF Validation in COVID-19 Patient Sample (Nuovo et al., 2020) Detection of SARS-CoV-2 proteins in nasopharyngeal swab cell preparations. B. An intense signal for covid-19 spike protein tested by SARS-CoV-2 spike antibodies (AAA10931) was observed in the glandular cells. F-H. Co-expression of spike detected by spike antibodies (AAA10931, 0.2 ug/mL) and envelope proteins detected by envelope antibodies (, 2 ug/mL) of SARSCoV- 2 (F) documented localization of each protein to glandular cells (G, yellow). No signal was seen in oral swabs of positive cases (H). Both the spike and envelope protein detected by anti-spike antibodies (AAA10931) and anti-envelope antibodies (,) produced a signal in the nasopharyngeal swabs of the three cases and no signal was evident in the nasopharyngeal swabs of the seven controls.)

IHC (Immunohistochemistry) (Figure 5 Immunohistochemistry Validation of SARSCoV-2 (COVID-19) Spike in COVID-19 Patient Lung Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti-SARS-CoV-2 (COVID-19) Spike S2 antibody (AAA10931, 0.5 ug/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong spike protein signal wasobserved in macrophages of COVID-19 patient lung.)

IHC (Immunohistochemistry) (Figure 4 Immunohistochemistry Validation of SARSCoV-2 (COVID-19) Spike in COVID-19 Patient Lung Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti-SARS-CoV-2 (COVID-19) Spike S2 antibody (AAA10931, 0.5 ug/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong spike protein signal was observed in macrophages and airway epithelium of COVID-19 patient lung, but not in non-COVID-19 patient lung.)

IF (Immunofluorescence) (Figure 3 Immunofluorescent Validation of AAA10931 in SARS-CoV-2 Infected Lung Tissue (Singh et al., Nature Microbiology, 2021) Multilabel confocal immunofluorescence microscopy of formalin-fixed paraffin-embedded lung sections from rhesus macaques infected with SARS-CoV-2. SARS-CoV-2 spike-specific antibodies, AAA10931. (k-s) (turquoise); Ki67 (magenta) and neutrophil marker CD66abce (yellow) (k-m); pan-macrophage marker CD68 (magenta) (n-p); HLA-DR (magenta) and pDC marker CD123 (yellow) (q–s) and DAPI (blue).)

IF (Immunofluorescence) (Figure 2 Immunofluorescent Validation of AAA10931 in SARS-CoV-2 Infected Nose and Tonsil (Singh et al., Nature Microbiology, 2021) Multi-label confocal immunofluorescence microscopy of nasal epithelium (20X-b, 63xh) and tonsil (20X-c,63X-i) from rhesus macaques infected with SARS-CoV-2 with SARS-CoV-2 spike-specific antibodies, AAA10931. (turquoise), DAPI (blue). Rabbit IgG isotype control antibody was used to stain the tissues to rule out any nonspecific staining (e, f).)

IF (Immunofluorescence) (Firure 1. Immunofluorescent Validation of AAA10931 in SARS-CoV-2 Infected Lung Tissue (Singh et al., Nature Microbiology, 2021)Multilabel confocal immunofluorescence microscopy of formalin-fixed paraffin-embedded lung sections from rhesus macaques infected with SARS-CoV-2. SARS-CoV-2 spike-specific antibodies, AAA10931. (k, n) (turquoise); Ki67 (magenta) and neutrophil marker CD66abce (yellow) (k); pan-macrophage marker CD68 (magenta) (n) and DAPI (blue).)

COVID 19 Spike Protein Coronavirus, Polyclonal Antibody (Cat# AAA10931)

Full Name

SARS-CoV-2 (COVID-19, 2019-nCoV) Spike Antibody

Reactivity

Virus

Applications

Immunofluorescence, Immunohistochemistry, Western Blot

Purity

SARS-CoV-2 (COVID-19, 2019-nCoV) Spike Antibody is affinity chromatography purified via peptide column.

Pricing

< >

<< Previous Next >>

IHC (Immunohistochemistry) (IHC Validation of Envelope in COVID-19 Patient Skin (Magro et al., 2020) Detection of SARS-CoV-2 Envelope protein in the blood vessels of COVID-19 patients that were confirmed by PCR. The staining shows Envelope protein expression (green) detected by envelope antibodies (AAA10932, 3 ug/mL) in the endothelial cytoplasms in thrombosed and normal appearing blood vessels with hematoxylin counterstain. The staining was negative in control normal skin/lung (not shown).)

IF (Immunofluorescence) (Co-expression of SARS-CoV-2 (COVID-19) Envelope and C5b-9 in Human Lung Tissue from the COVID-19 Patient Immunofluorescent l analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Envelope antibody (AAA10932, 2 ug/mL, red) and anti-C5b-9 antibody (green). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C, followed by secondary antibodies at 1/500 and DAPI staining (blue). Co- expression was shown in yellow. (Courtesy of Dr. Nuovo Gerard J., OSU).)

IF (Immunofluorescence) (Immunofluorescence Validation of SARS-CoV-2 (COVID-19) Envelope in Human Lung Tissue from the COVID-19 Patient Immunofluoorescent l analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Envelope antibody (AAA10932, 2 ug/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C, followed by a goat anti-rabbit IgG secondary antibody at 1/500 (red) and DAPI staining (blue). (Courtesy of Dr. Nuovo Gerard J., OSU).)

IF (Immunofluorescence) (IF Validation of Envelope in COVID-19 Patient Skin (Magro et al., 2020) Detection of SARS-CoV-2 Envelope protein in the skin of COVID-19 patients that were confirmed by PCR. The skin staining shows Envelope protein expression (green) detected by envelope antibodies (AAA10932, 3 ug/mL) in mononuclear cells with hematoxylin counterstain. The staining was negative in control normal skin/lung (not shown).)

IHC (Immunohistochemistry) (Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Envelope in COVID-19 Patient Lung Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Envelope antibody (AAA10932, 1 ug/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 envelope protein was observed in macrophage of COVID-19 patient lung, but not in non-COVID-19 patient lung.)

ELISA (Antibodies: SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope Antibody, (AAA10932) (1 ug/mL). A direct ELISA was performed using antigen or control peptide as coating antigen and the anti-SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 32 ng/mL to 2000ng/mL.)

IHC (Immunohistochemistry) (IHC Validation in COVID-19 Patient Sample. Detection of SARS-CoV-2 Envelope protein in nasopharyngeal swab samples of COVID-19 patients Panel F shows Envelope protein detected by envelope antibodies (AAA10932) was still evident 2 weeks after the initial swabs (signal is red with hematoxylin counterstain), though the amount of virus was much less than at the initial swab.)

IHC (Immunohistochemistry) (Validation in COVID-19 Patient Sample. Detection of SARS-CoV-2 proteins in nasopharyngeal swab cell preparations F-H. Co-expression of spike detected by spike antibodies and envelope proteins detected by envelope antibodies (AAA10932) of SARS-CoV-2 (panel F) documented localization of each protein to glandular cells with negative squamous cells two weeks after full revoery (panel G, signal yellow). No signal was seen in oral swabs of positive cases (Panel H). Both the spike and envelope protein detected by anti-spike antibodies and anti-envelope antibodies (AAA10932) produced a signal in the nasopharyngeal swabs of the three vases and no signal was evident in the nasopharyngeal swabs of the seven controls.)

COVID 19 Envelope Coronavirus, Polyclonal Antibody (Cat# AAA10932)

Full Name

SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody

Reactivity

Virus

Applications

Immunofluorescence, Immunohistochemistry

Purity

SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope Antibody is affinity chromatography purified via peptide column.

Pricing

< >

<< Previous Next >>

Application Data (Published customer image: Mouse anti Human cytochrome p450 aromatase antibody, clone H4 used for the detaction of aromatase in human tissues by Immunohistochemistry on paraffin sectionsImage caption:Morphology and P450 arom immunoreactivity of tumoral region in human testis with seminoma. A-B: Haematoxylin-eosin staining. C-D: Strong P450 arom immunoreactivity in cytoplasm of neoplastic cells (Nc) and unstained lymphocytes (L). Insert: absorption control. Scale bars: A, 20 um; B-C, 12.5 um; D, 5 um.From: Rago V, Romeo F, Aquila S, Montanaro D, And S, Carpino A. Cytochrome P450 aromatase expression in human seminoma. Reprod Biol Endocrinol. 2005 Dec 22;3:72.)

Application Data (Published customer image: Mouse anti Human cytochrome p450 aromatase antibody, clone H4 used for the detection of aromatase in rat prostate by immunohistochemistry on paraffin embedded sectionsImage caption:Immunohistochemical staining of aromatase in prostate of control and BPA-treated rats at doses of 25, 50, 300, or 600 ug/Kg/d for 4 days.From: Castro B, S¡nchez P, Torres JM, Preda O, del Moral RG, Ortega E. Bisphenol A exposure during adulthood alters expression of aromatase and 5a-reductase isozymes in rat prostate. PLoS One. 2013;8(2):e55905.)

Application Data (Published customer image: Mouse anti Human cytochrome p450 aromatase antibody, clone H4 used for the detaction of aromatase in human tissues by Immunohistochemistry on paraffin sectionsImage caption:P450 arom immunoreactivity in testicular region adjacent to seminoma and in controls A: Intense aromatase immunostaining in IGCN cells. B: Placental-like alkaline phosphatase staining of IGCN basal cells C: Strong aromatase immunoreactivity of interstitial Leydig cells in normal testis (Lc) D: Intense immunostaining of luteal cells (Luc) in ovarian tissue Scale bars: A-B, 8 um; C,12.5 um; D, 5 um.From: Rago V, Romeo F, Aquila S, Montanaro D, And S, Carpino A. Cytochrome P450 aromatase expression in human seminoma. Reprod Biol Endocrinol. 2005 Dec 22;3:72.)

Application Data (Published customer image: Mouse anti Human cytochrome p450 aromatase antibody, clone H4 use for the detection of aromatase in KGN cells by western blottingImage caption:Effect of H89 on aromatase and BRCA1 expression in KGN cells. A, The human ovarian granulosa cell line KGN were treated with control (DMSO), 20 mM H89, 50 mM PD98059, 200 nM Wortmannin, 100 nM Rapamycin 100 nM, and cells were harvested 24 hours after treatment. Immunoblotting was performed using specific antibodies against aromatase, BRCA1 and a-tubulin; B, Aromatase and BRCA1 mRNA levels were measured by real-time RT-PCR. Gapdh was used for normalizing the real time PCR results. The data are expressed as a fold (Aromatase mRNA), or a percentage (BRCA1 mRNA) relative to the DMSO-treated control.From: Ghosh S, Lu Y, Hu Y. A Role of CREB in BRCA1 Constitutive Promoter Activity and Aromatase Basal Expression. Int J Biomed Sci. 2008 Dec 15;4(4):260-265.)

Application Data (Western blot analysis of human placenta extract probed with Mouse anti Human Cytochrome P450 Aromatase followed by F(ab')2 Rabbit anti Mouse IgG:HRP)

Application Data (Published customer image: Mouse anti Human cytochrome p450 aromatase antibody, clone H4 used for the detection of aromatase in human lung tumors by immunohistochemistry on formalin fixed paraffin embedded tissue.Image caption:Representative immunohistochemistry of lung tumors for ERa, ERbeta, aromatase, EGFR and PR.From: Stabile LP, Dacic S, Land SR, Lenzner DE, Dhir R, Acquafondata M, Landreneau RJ, Grandis JR, Siegfried JM. Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res. 2011 Jan 1;17(1):154-64.)

Application Data (Published customer image: Mouse anti Human cytochrome p450 aromatase antibody, clone H4 used for the detection of aromatase in porcine spermatozoa by immunofluorescenceImage caption:Immunofluorescence labelling of androgen and estrogen receptors in pig spermatozoa: A) AR red fluorescence in sperm proximal mid-piece. B) P450arom red brilliant light in the proximal tail of sperm with a diffuse labelling in the distal tail. C) ERa red fluorescence in the sperm mid-piece, together with a faint labelling in the tail. D) ERbeta green intense light in the sperm acrosomal region. Inserts: immunonegative absorption controls. Scale bars: 5 um.From: Rago V, Aquila S, Panza R, Carpino A. Cytochrome P450arom, androgen and estrogen receptors in pig sperm. Reprod Biol Endocrinol. 2007 Jun 6;5:23.)

Application Data (Published customer image: Mouse anti Human cytochrome p450 aromatase antibody, clone H4 used for the detection of aromatase in sheep tissues by immunohistochemistry on paraffin sectionsImage caption:a and b) Low- (a) and higher- (b) power sections of the fetal end of a placentome in G1 stained with the prolactin antiserum and showing the intensely stained binucleate cells scattered along the trophoblast, but with a tendency to be more densely accumulated towards the fetal end (scale bars a=200?um; b=150?um). (c) High-power section of the trophoblast -endometrium interface in a placentome in G2 stained with the prolactin antiserum. Note the patchy staining of the thin, elongated endometrial epithelial cells (arrowed) in close contact with the intensely stained binucleate trophoblast cells (scale bar=40?um). (d) Low-power section of the intercotyledonary allantochorion stained with the prolactin antiserum and showing the relatively dense accumulation of binucleate trophoblast cells (arrowed) which remain unstained in this region of the placenta (scale bar=100?um). (e) High-power section at the edge of a placentome of G1 showing positive staining of the uninucleate trophoblast by the 3beta-HSD antiserum. The binucleate cells (arrowed) remain unstained (scale bar=40?um). (f) Section of the distended endometrial glands at the lateral border of a placentome in G2 stained with 3beta-HSD. The basal portions of the endometrial cells lining the glands stain strongly as does the secretory material adhered to the luminal surface of the cells and the accumulated coagulum, possibly as a result of ˜stickiness' of the material (scale bar=150?um). (g) High-power section of the intercotyledonary region of the allantochorion in G1 showing positive staining of the cytoplasm of the uninucleate, but not binucleate trophoblast by the 17,20 lyase antiserum (scale bar=40?um). (h) Section at the fetal end of a placentome from G2 remaining unstained by the aromatase antiserum (scale bar=150?um). (i) Section of near-term sheep placenta showing strong, positive staining of the uninucleate, but not binucleate, trophoblast by the aromatase antiserum (scale bar=150?um). (j) High-power section at the fetal end of a placentome in G1 showing strong positive staining of the uninucleate trophoblast by the PR antiserum. The binucleate cells (arrowed) remain unstained (scale bar=40?um).From: Wilsher S, Stansfield F, Greenwood RE, Trethowan PD, Anderson RA, Wooding FB, Allen WR. Ovarian and placental morphology and endocrine functions in the pregnant giraffe (Giraffa camelopardalis). Reproduction. 2013 May 21;145(6):541-54.)

Application Data (Published customer image: Mouse anti Human cytochrome p450 aromatase antibody, clone H4 used for the detection of aromatase in human synovial tissue by immunohistochemistry on cryosectionsImage caption:Aromatase expression in synovial tissue and endogenous steroid hormone release from superfused synovium. (a) Immunohistochemistry of aromatase in one OA and one RA patient. Using the respective control antibody revealed no staining of positive cells (not shown). Magnification: 400x. (b) Density of aromatase-positive cells in OA (open bars, n = 20) and RA patients (hatched bars, n = 16). (c) Spontaneously released E2, E3, and free testosterone from standardized superfused pieces of synovial tissue of OA (open bars, n = 20) and RA patients (hatched bars, n = 18). (b,c) Values are given as box blots with the 5th, 25th, 50th (median), 75th, and 95th percentile when applicable. OA, osteoarthritis; RA, rheumatoid arthritis. Other abbreviations are as given in the legend to Fig. 1.From: Schmidt M, Weidler C, Naumann H, Anders S, Sch¶lmerich J, Straub RH. Androgen conversion in osteoarthritis and rheumatoid arthritis synoviocytes--androstenedione and testosterone inhibit estrogen formation and favor production of more potent 5alpha-reduced androgens. Arthritis Res Ther. 2005;7(5):R938-48.)

CYTOCHROME P450 AROMATASE, Monoclonal Antibody (Cat# AAA12113)

Full Name

MOUSE ANTI HUMAN CYTOCHROME P450 AROMATASE

Gene Names

CYP19A1; ARO; ARO1; CPV1; CYAR; CYP19; CYPXIX; P-450AROM

Applications

Immunofluorescence, Immunohistochemistry, Western Blot

Pricing

Loading...

Filters

Clonality

Type

Reactivity

Gene Name

Isotype

Host

Application

Clone

4 results for "PCR POSITIVE CONTROLS" - showing 1-4

CD229, Monoclonal Antibody (Cat# AAA11951)

COVID 19 Spike Protein Coronavirus, Polyclonal Antibody (Cat# AAA10931)

COVID 19 Envelope Coronavirus, Polyclonal Antibody (Cat# AAA10932)

CYTOCHROME P450 AROMATASE, Monoclonal Antibody (Cat# AAA12113)

Loading...

Need a datasheet, manual, COA, or MSDS? Have a question?

Interested to get a quote about our products?

Filters

Clonality

Type

Reactivity

Gene Name

Isotype

Host

Application

Clone

4 results for "PCR POSITIVE CONTROLS" - showing 1-4

CD229, Monoclonal Antibody (Cat# AAA11951)

COVID 19 Spike Protein Coronavirus, Polyclonal Antibody (Cat# AAA10931)

COVID 19 Envelope Coronavirus, Polyclonal Antibody (Cat# AAA10932)

CYTOCHROME P450 AROMATASE, Monoclonal Antibody (Cat# AAA12113)

Submit a Question

Request more Information

Request a Manual

Request a Quote